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CORRESPONDENCE
Letters to the Editor
Dear Sir,
In their interesting contribution to Seizure, Kwan
and Brodie1 reported on experiences in the Epilepsy
Unit of the Western Infirmary with patients that failed
on their first monotherapy drug. When failure was
due to a lack of efficacy, either AED substitution
or combination was undertaken. When failure was
due to adverse effects the drug was substituted by
alternative monotherapy. When these latter patients
were not seizure free on their first tolerated drug, they
also received either AED substitution or combination.
The combined results of patients receiving either
AED substitution or combination are reported and
combination therapy appears to be an effective
treatment in this category of patients. In particular,
combinations of a sodium channel blocker with a
drug with multiple mechanisms were associated with a
favourable outcome. These observational results are in
agreement with a literature review by our group2 and
merit further prospective investigation. However, their
paper also raises some questions:
(1) The distinction made between patients that fail
on their first monotherapy drug due to lack of
efficacy and those that failed due to adverse
effects is somewhat puzzling. Did the patients
that failed due to a lack of efficacy do so on
a maximally tolerated dose? Were the patients
that failed due to adverse effects seizure free, or
could this not yet be determined?
(2) In a paper by the same authors in the New
England Journal of Medicine3, a large differ-
ence was reported in the proportion of patients
that eventually became seizure free between the
patients that failed on their first monotherapy
drug due to lack of efficacy and those that failed
due to adverse effects. This difference does not
seem that clear to us in the present paper.
(3) The authors report that some ‘mechanistic’
combinations were associated with better ef-
fectiveness than others, but did they also find
that mechanisms of action should be taken into
account when choosing a substitution monother-
apy drug? In other words, was substitution more
successful when a sodium channel blocker was
substituted by a drug with multiple mechanisms
of action and vice versa?
C. L. P. Deckers
P. D. Knoester
On behalf of the Nijmegen Epilepsy Research Group,
University Medical Centre Nijmegen,
Nijmegen, The Netherlands
Dear Sir,
We are grateful to Deckers and his colleagues for
their interest in our outcome studies4, 5. The aim of
the project was to follow patients from their first
antiepileptic drug (AED) to seizure freedom or re-
fractoriness, and document the factors influencing the
likelihood of either eventuality. The results suggested
that there are two populations of patients4. Around
60% will be controlled on the first or second (AED)
as monotherapy. The majority of the remainder will
require polypharmacy or became intractable to all
pharmacological manipulations. The most powerful
predictor for ‘refractoriness’ was failure on the first
AED due to lack of efficacy. By this we meant
that high AED dosage was achieved without side-
effects but continuing seizures. Only 11% of these
patients subsequently became seizure free. Patients
who tolerated the first drug poorly, i.e. developed
symptoms on a modest dose and never became seizure
free, did rather better long term with more than
40% subsequently being controlled on alternative
medication. The Seizure paper5 looked at the clinical
course in the 248 patients in whom treatment with the
first AED failed. There was a trend to better outcome
with duotherapy than substitution5. Individual dosing
data will be published in a third paper, which is
currently in the hands of the reviewers6. These results
served to generate a range of hypotheses that needs to
be tested more rigorously with randomized studies.
We aim to re-evaluate our population of untreated
patients 5 years on, hoping to show that a higher
percentage became seizure-free patients with ‘ratio-
nal’ combination strategies using the newer AEDs
as touched upon in the Seizure paper5. In partic-
ular, we have seen good results combining sodium
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valproate with lamotrigine7 and carbamazepine with
topiramate8. The analysis plan will also look at the
success or otherwise of substitution with drugs with
different mechanisms of action. The original study
threw up many such questions that we did not address.
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